Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 48-week results from a multicentre, randomised, double-blind, phase 2b study.
Weekly pemvidutide improved markers of liver inflammation and fibrosis in adults with fatty liver disease, offering hope for slowing liver damage progression.
This multicenter randomized double-blind phase 2b trial examined Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 48-week results from a multicentre, randomised, double-blind, phase 2b study. In patients with MASH, 48 weeks of pemvidutide treatment led to significant reductions in non-invasive tests of MASH inflammation and fibrosis, suggesting continued improvement in liver health.
What the study was
- Study design
- Multicenter randomized double-blind phase 2b trial
- Sample size
- 41
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- The lancet. Gastroenterology & hepatology
Why it surfaced
Retained after review of PubMed metadata and abstract because its multicenter randomized double-blind phase 2b trial directly informs cardiovascular-metabolic; scoring was capped conservatively for design and evidence maturity.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.